Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Current Leases (2022 - 2026)

Sagimet Biosciences' Current Leases history spans 5 years, with the latest figure at $39000.0 for Q1 2026.

  • Quarterly Current Leases changed 0.0% to $39000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $39000.0 through Mar 2026, changed 0.0% year-over-year, with the annual reading at $78000.0 for FY2025, 0.0% changed from the prior year.
  • Current Leases came in at $39000.0 for Q1 2026, down from $78000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $153000.0 in Q2 2024 to a low of $26000.0 in Q1 2024.
  • The 5-year median for Current Leases is $103000.0 (2023), against an average of $95153.8.
  • Year-over-year, Current Leases plummeted 51.13% in 2023 and then soared 50.0% in 2025.
  • Sagimet Biosciences' Current Leases stood at $133000.0 in 2022, then tumbled by 51.13% to $65000.0 in 2023, then rose by 20.0% to $78000.0 in 2024, then changed by 0.0% to $78000.0 in 2025, then plummeted by 50.0% to $39000.0 in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Current Leases are $39000.0 (Q1 2026), $78000.0 (Q4 2025), and $115000.0 (Q3 2025).